Advertisement

The Clinical Potential of DNA Content Parameters in Human Pediatric and Adult Solid Tumors

  • Mark Zalupski
  • John F. Ensley
Part of the Developments in Oncology book series (DION, volume 77)

Abstract

The ability to predict the natural history and treatment outcome of human cancers, particularly for an individual patient, has long been a goal of cancer researchers. Knowledge concerning the natural history of a particular cancer was acquired by careful clinical observation long before effective treatments were developed and eventually evolved into our current clinical staging systems. Over the last century, light microscopic and tissue staining technologies have evolved which have allowed the careful correlation of pathological features of tumors and the clinical outcome of the patients that harbor them. Until very recently, individual patient treatment decisions and the design of clinical trials were based primarily on these two types of parameters; clinical stage and histopathology.

Keywords

Homogeneously Staining Region Adult Solid Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Look AT, Hayes FA, Nitschke R, et al: Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N. Engl. J. Med. 311:231–235, 1984.PubMedCrossRefGoogle Scholar
  2. 2.
    Gansler T, Chatten J, Varello M, et al: Flow cytometric DNA analysis of neuroblastoma. Correlation with histology and clinical outcome. Cancer 58: 2453–2458, 1986.PubMedCrossRefGoogle Scholar
  3. 3.
    Oppedal BR, Storm-Mathisen I, Lie SO, Brandtzaeg P: Prognostic factors in neuroblastoma. Clinical, histopathologic, and immunohistochemical features and DNA ploidy in relation to prognosis. Cancer 62:772–780, 1988.PubMedCrossRefGoogle Scholar
  4. 4.
    Naito M, Iwafuchi M, Ohsawa Y, et al: Flow cytometric DNA analysis of neuroblastoma: Prognostic significance of DNA ploidy in unfavorable group. J. Ped. Sur. 26:834–837, 1991.CrossRefGoogle Scholar
  5. 5.
    Cohn SL, Rademaker AW, Salwen HR, et al: Analysis of DNA ploidy and proliferative activity in relation to histology and N-myc amplification in neuroblastoma. Am. J. Path. 136:1043–1051, 1990.PubMedGoogle Scholar
  6. 6.
    Bourhis J, DeVathaire F, Wilson GD, et al: Combined analysis of DNA ploidy index and N-myc genomic content in neuroblastoma. Cancer Res. 51:33–36, 1991.PubMedGoogle Scholar
  7. 7.
    Look AT, Hayes FA, Shuster JJ, et al: Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: A pediatric oncology group study. J. Clin. Oncol. 9:581–591, 1991.PubMedGoogle Scholar
  8. 8.
    Brodeur GM: Neuroblastoma: Clinical significance of genetic abnormalities. Cancer Surveys 9:673–685, 1990.PubMedGoogle Scholar
  9. 9.
    Boyle ET Jr, Reiman HM, Kramer SA, et al: Embryonal rhabdomyosarcoma of bladder and prostate: Nuclear DNA patterns studied by flow cytometry. J. Urol. 140:1119–1121, 1988.PubMedGoogle Scholar
  10. 10.
    Molenaar WM, Dam-Meiring A, Kamps WA, Cornelisse CJ: DNA-Aneuploidy in rhabdomyosarcomas as compared with other sarcomas of childhood and adolescence. Hum. Pathol. 19:573–579, 1988.Google Scholar
  11. 11.
    Shapiro DN, Parham DM, Douglass EC, et al: Relationship of tumor-cell ploidy to histologic subtype and treatment outcome in children and adolescents with unresectable rhabdomyosarcoma. J. Clin. One. 9:159–166, 1991.Google Scholar
  12. 12.
    Bauer HCF: DNA Cytometry of Osteosarcoma. Acta Orthop. Scand. 59 (suppl. 228):l-39, 1988.Google Scholar
  13. Gebhardt MC, Lew RA, Bell RS, et al: DNA ploidy as a prognostic indicator in human osteosarcoma. Proc. Eur. Musculoskeletal One. Soc. Bologna, Italy, suppl. 1:18–21, 1990.Google Scholar
  14. 14.
    Look AT, Douglass EC, Meyer WH: Clinical importance of near-diploid tumor stem lines in patients with osteosarcoma of an extremity. N. Engl. J. Med. 318:1567–1572, 1988.PubMedCrossRefGoogle Scholar
  15. 15.
    Bosing T, Roessner A, Hiddemann W, et al: Cytostatic effects in osterosarcomas as detected by flow cytometric DNA analysis after preoperative chemotherapy according to the COSS 80/82 protocol. J. Cancer Res. Clin. Oncol. 113:369–375, 1987.PubMedCrossRefGoogle Scholar
  16. Baldini N, Gebhardt MC, Springfield DS, et al: Effect of preoperative chemotherapy on nuclear DNA content in osteosarcoma. Proc. of Eur. Musculo-skeletal One. Soc, Bologna, Italy, suppl. 1:22–24, 1990.Google Scholar
  17. 17.
    McDivitt RW, Stone KR, Craig B, et al: A proposed classification of breast cancer based on kinetic information. Cancer 57:269–276, 1986.PubMedCrossRefGoogle Scholar
  18. 18.
    Frankfort OS, Hüben RP: Clinical applications of DNA flow cytometry for bladder tumors. Urol. Supp. 23:29–34, 1984.Google Scholar
  19. 19.
    Zetterberg A, Esposti PL: Prognostic significance of nuclear DNA levels in prostatic carcinoma. Scand. J. Urol. Nephrol. 55:53–58, 1980.Google Scholar
  20. 20.
    Otto LL, Baisch H, Hulano H, Klöppel G: Tumor cell deoxyribonucleic acid content and prognosis in human renal carcinoma. J. Urol. 132:237–239, 1984.PubMedGoogle Scholar
  21. 21.
    Wolley RC, Schreiber K, Koss LG, et al: DNA distribution in human colon carcinoma and its relationship to clinical behavior. J. Natl. Cancer Inst. 69:15–22, 1982.PubMedGoogle Scholar
  22. 22.
    Volm M, Hahn EW, Mattern J, Vogt-Moykopf I: Independent flow cytometric prognostic factors for the survival of patients with non-small cell lung cancer: A five year follow up study. Proc. AACR 29:26, 1988.Google Scholar
  23. 23.
    Woodbridge TN, Grierson HL, Pierson JL, et al: DNA aneuploidy and low proliferative activity predict a favorable clinical outcome in diffuse large cell lymphoma. Proc. AACR 28:131, 1987.Google Scholar
  24. 24.
    Brifford M, Spyratos F, Tubiana-Hulin M, et al: Analysis of breast carcinoma response to chemotherapy by sequential cytopunctures: Influence of DNA analysis, morphological changes and histology on tumor regression. Proc. ASCO 7:34, 1988.Google Scholar
  25. 25.
    Tomita T, Yasue M, Englehard HH, et al: Flow cytometric DNA analysis of medulloblastomas. Prognostic implications of ploidy. Cancer 61:744–749, 1988.PubMedCrossRefGoogle Scholar
  26. 26.
    Oppedal BR, Strom-Mathisen I, Lie SO, Brandtzaeg P: Prognostic factors in neuroblastomas: Clinical, histopathologic, and immunohistochemical featues and DNA ploidy in relation to prognosis. Cancer 62:772–780, 1988.PubMedCrossRefGoogle Scholar
  27. 27.
    Meyer JS, Priolea PG: S-phase fractions of colorectal carcinomas related to pathologic and clinical features. Cancer 48:1221–1228, 1981.PubMedCrossRefGoogle Scholar
  28. 28.
    Bell RS, Mankin HJ, Gebhardt MC, Lee R: Disease free survival and tumor ploidy in high grade osteosarcoma. Proc. 10th Annual Meeting Cell Kinetics Society, Santa Fe, New Mexico, p. 30, 1986.Google Scholar
  29. 29.
    Rosell R, Gomez-Codina J, Camps C, et al: Favorable outcome and aneuploidy reversion following neoadjuvant chemotherapy in stage IIIA non-small cell lung cancer. Proc. ASCO 11:954, 1992.Google Scholar
  30. 30.
    Jacobsen AB, Berner A, Juul M, et al: Prognostic significance of deoxyribonucleic acid flow cytometry in muscle invasive bladder carcinoma treated with preoperative radiation and cystectomy. J. Urol. 147:34–37, 1992.PubMedGoogle Scholar
  31. 31.
    Al-Sarraf M, Kish J, Ensley JF: Head and neck cancer. The Wayne State University Experience with Adjuvant Chemotherapy. Hem. One. Clinics North Amer. 5:687–700, 1991.Google Scholar
  32. 32.
    Ensley JF, Maciorowski Z, Kish JA, Al-Sarraf M: The significance of pretreatment identification of prognostically important subgroups of squamous cell cancer of the head and neck. In: Scientific and Clinical Perspective of Head and Neck Cancer Manaement. Strategies for Cure, J Jacobs, M Al-Sarraf, J Crissman, F Valeriote (ed), Elsevier Inc., NY, pp. 35–56, 1987.Google Scholar
  33. 33.
    Ensley J, Kish J, Tapazoglou E, et al: The justification and strategies for the continued intensification of induction regimens in patients with advanced, untreated head and neck cancer. In: Head and Neck Oncology Research. Proceedings of the Second International Research Conference on Head and Neck Cancer, 1987, GT Wolf, T Carey (ed), Kugler Pub., Amsterdam, pp. 313–321, 1988.Google Scholar
  34. 34.
    Al-Kourainy K, Kish JA, Ensley JF, et al: Achievement of superior survival for histologically negative vs histologically positive clinically complete responders to cis-platinum combinations in patients with locally advanced head and neck cancer. Cancer 59:233–238, 1987.PubMedCrossRefGoogle Scholar
  35. 35.
    Ensley JF, Kish JA, Jacobs J, et al: Incremental improvements in median survival associated with degree of response to adjuvant chemotherapy in patients with advanced squamous cell cancer of the head and neck. In: Adjuvant Therapy of Cancer, Vol. IV, SE Jones, SE Salmon (ed), Grune & Stratton, Orlando, pp. 117–126, 1984.Google Scholar
  36. 36.
    Looser KG, Shah JP, Strong EW: The significance of “positive” margins in surgically resected epidermoid carcinomas. Head and Neck Surgery 1:107–111, 1978.PubMedCrossRefGoogle Scholar
  37. 37.
    Ervin TJ, Clark JR, Weichselbaum RR, et al: An analysis of induction and adjuvant chemotherapy in multidisciplinary treatment of squamous-cell carcinoma of the head and neck. J. Clin. Oncol. 5:10–20, 1987.PubMedGoogle Scholar
  38. 38.
    Wolf GT, et al: Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advacned laryngeal cancer. N. Engl. J. Med. 324:1685–1690, 1991.CrossRefGoogle Scholar
  39. 39.
    Adjuvant chemotherapy for advanced head and neck squamous carcinoma: Final report of the Head and Neck Contracts Program. Cancer 59:301–311, 1987.CrossRefGoogle Scholar
  40. 40.
    Goldsmith MM, Cresson DH, Postma DS, et al: The significance of ploidy in laryngeal cancer. Am. J. Surg. 152:396–402, 1986.PubMedCrossRefGoogle Scholar
  41. 41.
    Sickle-Santanello BJ, Farrar WB, Dobson JL, et al: Flow cytometry as a prognostic indicator in squamous cell carcinoma of the tongue. Am. J. Surg. 152:393–395, 1986.PubMedCrossRefGoogle Scholar
  42. 42.
    Kokal RL, Gardine K, Sheibani IW, et al: Tumor DNA content as a prognostic indicator in squamous cell carcinoma of the head and neck region. Proc. ASCO 7:149, 1988.Google Scholar
  43. 43.
    Gussack GS, Donelly K, Hester R, Dowling E: Flow cytometric DNA analysis of laryngeal carcinomas. In: Head and Neck Oncology Research. Proceedings of the Second International Research Conference on Head and Neck Cancer, 1987, GT Wolf, T Carey (ed), Kugler Pub., Amsterdam, pp. 241–249, 1988.Google Scholar
  44. 44.
    Kaplan AS, Caldarelli DD, Chacho MS, et al: Retrospective DNA analysis of head and neck squamous cell carcinoma. Arch. Otolaryngol. Head and Neck Surg. 112:1159–1162, 1986.Google Scholar
  45. 45.
    de Braud F, Ensley JF, Hassan M, et al: Prospective correlation of clinical outcome in patients with advanced, resectable squamous cell carcinomas of the head and neck (SCCHN) with DNA ploidy from fresh specimens. Proc AACR 30:1046, 1989.Google Scholar
  46. 46.
    Ensley J, Maciorowski Z, Pietraskiewicz H, et al: Prognostic impact of cellular DNA parameters in neoadjuvant and adjuvant trials of patients with head and neck (H&N) cancer. In: Adjuvant Therapy of Cancer, Vol. VI, SE Salmon (ed), Grune & Stratton, Orlando, pp. 101–108, 1990.Google Scholar
  47. 47.
    Ensley JF, Maciorowski Z, Pietraszkiewicz H, et al: Methodology and clinical applications of cellular DNA content parameters determined by flow cytometry in squamous cell cancers of the head and neck. Cancer Treat. Rep. 52:225–242, 1990.Google Scholar
  48. 48.
    Sakr W, Hassan M, Hassan M, et al: DNA quantitation and histologic characteristics of squamous cell carcinomas of the upper aerodigestive tract. Arch. Pathol. Lab. Med. 113:1009–1014, 1989.PubMedGoogle Scholar
  49. 49.
    Holm LE: Cellular DNA amounts of squamous cell carcinomas of the head and neck region in relation to prognosis. Laryngoscope 92:1064–1069, 1982.PubMedCrossRefGoogle Scholar
  50. 50.
    Franzen G, Olofsson J, Tytor M, et al: Preoperative irradiation in oral cavity carcinoma. A study with special reference to DNA pattern, histological response and prognosis. Acta Oncol. 26:349–355, 1987.PubMedCrossRefGoogle Scholar
  51. 51.
    Nervi C, Badaracco G, Morelli M, Starace G: Cytokinetic evaluation in human head and neck cancer by autoradiography and DNA cytofluorometry. Cancer 45:452–459, 1980.PubMedCrossRefGoogle Scholar
  52. 52.
    Roa RA, Carey TE, Passamani PP, et al: DNA content of human squamous cell carcinoma lines. Analysis by flow cytometry and chromosome enumeration. Arch. Otolaryngol. 111:565–575, 1985.PubMedGoogle Scholar
  53. Proceedings of the Third International Head and Neck Oncology Research Conference, Las Vegas, 1990.Google Scholar
  54. 54.
    Ensley JF, Maciorowski Z, Hassan M, et al: Cellular DNA parameters in untreated and recurrent squamous cell cancers of the head and neck. Cytometry 10:334–338, 1989.PubMedCrossRefGoogle Scholar
  55. 55.
    Ensley J, Maciorowski Z, Hassan M, et al: Prospective correlations of flow cytometry (FCM) DNA parameters (DNA Index and % SPF) and cytotoxic response in previously untreated patients with advanced squamous cell cancers of the head and neck. Proc. AACR 29:105, 1988.Google Scholar
  56. Tennvall J, Wennergerg J, Anderson H, et al: DNA analysis as a predictor of the outcome of induction chemotherapy in advanced head and neck carcinomas. Arch. Otolaryngol. — Head and Neck Surgery, In press.Google Scholar
  57. 57.
    Cooke LD, Cooke TG, Bootz F, et al: Ploidy as a prognostic indicator in end stage squamous cell carcinoma of the head and neck region treated with cisplatinum. Br. J. Cancer 61:759–762, 1991.CrossRefGoogle Scholar
  58. 58.
    Ensley J, Maciorowski Z, Pietraszkiewicz H, Reed M: DNA ploidy transformations in new head and neck cancer cell lines (SCCHN): Implications for cytotoxic therapy. Proc. AACR 31:23, 1990.Google Scholar
  59. Ensley J, Maciorowski Z, Pear A, et al: The selection of patients for clinical trials with squamous cell cancers of the head and neck (SCCHN) based on the existence of pure DNA aneuploid tumors documented by multiparameter flow cytometry. Proc. ASCO, 1993, In press.Google Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • Mark Zalupski
  • John F. Ensley

There are no affiliations available

Personalised recommendations